What is FOXG1 Syndrome?
FOXG1 syndrome is a rare neurological genetic disorder that impacts brain development and typically causes epilepsy, as well as a spectrum of severe to moderate physical and cognitive disabilities. Mutations to the FOXG1 gene are mostly (de-novo) non-inherited. There are currently about 700 known people in the world diagnosed with FOXG1 syndrome.
FOXG1 holds the key to unlock brain disorders affecting millions, including autism, Alzheimer's, brain tumors and many more.
FOXG1 is an excellent candidate for gene therapy and biotech investment.
Watch the FOXG1 Research Story…
“The FOXG1 Research Foundation is a parent-led Patient Organization on the fast-track to success. They’ve accomplished more in their first year than most do in ten.”
- Jeremy Levin, CEO Ovid Therapeutics
Scientific Advisory Board
Orrin Devinsky, MD
Neurosurgeon, NYU Langone, Chief of Service, NYU Epilepsy
Robin Kleiman, Ph.D
Senior Director, Biogen Research Associate, Boston Children’s Hospital
Kiran Reddy, MD
CEO, Praxis Precision Medicines, Former Partner, Clarus Ventures
Aris Economides, PhD
Vice President of Research, Regeneron Pharmaceuticals
Steven Gray, PhD
Scientist, Gene Therapy Center at UNC School of Medicine
Ingrid Scheffer, MD, PhD
Neurologist and Senior Research Fellow, Florey Institute of Neuroscience and Mental Health
Elli Brimble, MSc, MS, CGC
Geneticist, Lucille Packard Children’s Hospital at Stanford
Neil Kumar, PhD
CEO, BridgeBio Pharma, Former Principal, Third Rock Ventures
Heather Olson, MD, MS
Neurologist, Boston Children's; Neurology Instructor, Harvard Medical
Xilma Ortiz-Gonzalez, MD, PhD
Pediatric Neurologist, CHOP, Neurology Instructor, University of Pennsylva
Mary Jones, MD
Pediatrician, Head, Katie's RETT Clinic at UCSF Oakland
Gordon Fishell, PhD
Scientist, Broad Institute; Professor, Harvard Medical School
Hourinaz Behesti, PhD
Developmental Neurobiologist, Rockefeller University
Adam James Waite, PhD
Scientist, Calico Life Sciences, LLC
Toni Cathomen, PhD
Director, Institute for Cell and Gene Therapy, University of Freiburg
Justin To
Chief Operating Officer of BridgeBio Gene Therapy
Ritu Lal, PhD
Clinical Pharmacology Consultant
Mark Pykett, PhD
Chief Innovation Officer, PTC Therapeutics, former CEO, Agilis Biotherapeutics
Dr Nadia Bahi-Buisson, MD, PhD
Pediatric Neurology, Necker Enfants Malades University Hospital, Paris
Dr Scott Dindot, PhD
Assistant Professor, Texas A&M College of Medicine